caladrius
BIOSCIENCES

COMPANY OVERVIEW

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company's current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who have experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia ("CLI") based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction ("CMD"); and CLBS14, a Regenerative Medicine Advanced Therapy ("RMAT") designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the "FDA") a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina ("NORDA").

INVESTMENT HIGHLIGHTS

- CD34+ cell therapy company with an advanced clinical pipeline with 2 programs with "breakthrough" designation and 1 targeting COVID-19 induced lung repair
- Proprietary field-leading technology in multi-billion-dollar global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12-18 months based on development milestones across the pipeline (some timing COVID-19 dependent)
- Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
- Strong balance sheet; ~$42 million in cash & cash equivalents (July 31, 2020) with no debt and cash runway projected to fund operations through 2021

C-SUITE LEADERSHIP TEAM

David Mazzo, PhD
President and Chief Executive Officer

Douglas Losordo, MD
Executive Vice President, Global Head of R&D, and Chief Medical Officer

MARKET SNAPSHOT

Ticker Symbol	CLBS
Exchange	NASDAQ
52-Week Price Range	$1.05 - $3.64
Shares Outstanding *(7/31/2020)*	19.3 million
Cash & Investments *7/31/2020)*	~$42 million
Fiscal Year-End	December 31

POTENTIAL VALUE CREATING MILESTONES

❑ **3Q 2020**	Initiation of CLBS119 Pilot Study
❑ **2H 2020**	HONEDRA® J-NDA Rolling Submission Initiation
❑ **4Q 2020**	Initiation of CLBS16 Phase 2b trial
❑ **YE 2020**	Complete Phase 2 HONEDRA® enrollment
❑ **YE 2021**	Announce Phase 2 HONEDRA® top-line data

CD34+ CELL THERAPY PIPELINE

Product	Indication	Development Stage	Commercialization Target[1]
CLBS119	COVID-19 Lung Damage	Pilot *(USA; start target 3Q 2020)*	TBD
HONEDRA® *(formerly CLBS12)*	CLI	Registration eligible trial *(Japan; ongoing)*	mid-2022
CLBS16	CMD	Phase 2b *(USA; start target 4Q 2020)*	TBD
CLBS14	NORDA	Phase 3 confirmatory *(USA; initiation pending funding)*	TBD

CD34+ CELL THERAPY PLATFORM

- Naturally occurring vascular repair (endothelial progenitor) cell
- Provokes restorative angiogenesis of the microvasculature
- CD34+ cells re-establish blood flow to under-perfused tissues



- CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation
- CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius' proprietary platform technology selects and delivers a potent, concentrated population of the patient's own CD34+ cells for optimal therapeutic benefit.



- Drug induced mobilization eliminates need for surgical bone marrow aspiration
- No genetic manipulation or ex vivo expansion of cells
- Four days or less from donation to treatment
- Cost-of-goods an order of magnitude less expensive than CAR-T therapies

CALADRIUS BIOSCIENCES, INC.
www.caladrius.com

CORPORATE HEADQUATERS
110 Allen Road, 2nd Floor
Basking Ridge, NJ 07920
Tel: 908.842.0100

INVESTOR RELATIONS CONTACT
John D. Menditto
Tel: 908.842.0084
Email: jmenditto@caladrius.com

The information contained herein was obtained from Caladrius Biosciences, Inc. This does not constitute the solicitation of the purchase or sale of securities. Except for the historical information contained in this summary, the matters discussed herein are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Caladrius undertakes no obligation to update or revise any forward-looking statements. For additional information about Caladrius Biosciences and its operations and related risks, please refer to the Company's SEC filings.
Caladrius © 2020 All rights reserved